Fast, clean, and quantitative protein conjugation using genetically encoded tetrazine amino acids

Overview

This technology addresses a critical bottleneck in bioconjugation: achieving fast, clean, and quantitative protein labeling that is site-specific and compatible with all biological conditions. Conventional protein conjugation methods—including protein-drug conjugation and protein-protein conjugation—are hampered by incomplete reactions, lack of site-specific attachment, and harsh reaction conditions incompatible with many proteins. This platform uses a genetically encoded amino acid combined with fast labeling chemistry to deliver complete conjugation in minutes, even under dilute protein conditions where most proteins remain stable.

The approach is broadly applicable across therapeutic, diagnostic, and industrial biotechnology workflows, enabling partners to produce precisely labeled protein conjugates for downstream applications such as antibody-drug conjugates, nanobody assemblies, and immobilized enzymes.

Technical specifications

• Genetically encoded tetrazine amino acid enables site-specific incorporation into target proteins at defined positions.
• Reaction rates exceeding 10,000 M⁻¹s⁻¹ drive labeling to completion in minutes, eliminating the need for post-labeling purification.
• Compatibility with dilute protein conditions preserves protein stability and function throughout the conjugation process.
• Mild, biologically compatible reaction conditions ensure broad applicability across diverse protein targets.
• Validated applications include eukaryotic cell labeling, nanobody assembly construction, and surface immobilization of enzymes with controlled orientation and load.
• Scalable expression and labeling workflows can be tailored to client-specific proteins, cell systems, and production scales.

Technology readiness level

The technology has been validated through multiple peer-reviewed publications demonstrating protein labeling and protein-protein conjugation capabilities across eukaryotic cells, nanobody systems, and surface-immobilized enzymes. The platform is ready for collaborative development and client-specific projects. Future validation activities include developing genetic encoding systems for client target proteins, performing site-specific labeling with client-selected molecules, verifying conjugate purity by mass spectrometry, assessing activity of labeled conjugates, and scaling expression and labeling methods to meet partner needs. Timelines and costs depend on protein complexity, expression system requirements, and the number of conjugates needed.